692-13-7
692-13-7 结构式
基本信息
W 37
H 224
Glybigid
Buformin
Butformin
Buformine
Dibetos B
Butyldiguanide
Butylbiguanide
常见问题列表
Buformin (0-10 mM; 5 days) inhibits SKBR3 and BT474 cells growth as a concentration-dependent manner, exhibits IC 50 values of 246.7 μM and 98.6 μM for erbB-2-overexpressing SKBR3 and BT474 cells, respectively.Buformin (0-3 mM; 48 hours) increases the percentage of cells in G0/G1 phase and reduced the percentage of cells in S phase, especially in the SKBR3 cells.Buformin (0-3 mM; 24 hours) suppresses RTK activation, including erbB-2 and IGF1R signaling downstream, and Akt activation/phosphorylation is inhibited in both SKBR3 and BT474 cells.
Cell Viability Assay
| Cell Line: | ErbB-2-overexpressing SKBR3 and BT474 cells |
| Concentration: | 0 μM, 1 μM, 3 μM, 10 μM, 30 μM, 100 μM, 300 μM, 1, 3, or 10 mM |
| Incubation Time: | 5 days |
| Result: | Reduced cell viability in erbB-2-overexpressing breast cells. |
Cell Cycle Analysis
| Cell Line: | ErbB-2-overexpressing SKBR3 and BT474 cells |
| Concentration: | 0.5 mM; 1 mM; 3 mM |
| Incubation Time: | 48 hours |
| Result: | Increased cells arresting in G0/G1 phase. |
Western Blot Analysis
| Cell Line: | ErbB-2-overexpressing SKBR3 and BT474 cells |
| Concentration: | 0 mM, 0.1 mM, 0.3 mM, 1 mM, or 3 mM |
| Incubation Time: | 24 hours |
| Result: | Decreased p-AMPK, p-p706S, p-ERK1/2 expression in a concentration-dependent manner. |
Buformin (oral administation; 7.6 mmol/kg of chow; 7 days) exhibits significantly reduced tumor volumes and weights, and hinders mammary morphogenesis and proliferation in MMTV-erbB-2 transgenic mice
| Animal Model: | Female MMTV-erbB-2 transgenic mice |
| Dosage: | 7.6 mmol/kg |
| Administration: | Oral administation; 7 days |
| Result: | Inhibited mammary syngeneic tumor growth in MMTV-erbB-2 transgenic mice. |